Ignite Creation Date:
2025-12-25 @ 3:23 AM
Ignite Modification Date:
2026-04-23 @ 1:51 AM
Study NCT ID:
NCT02757105
Status:
COMPLETED
Last Update Posted:
2018-08-28
First Post:
2016-04-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Sponsor:
RedHill Biopharma Limited
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-05-19
Start Date Type:
ACTUAL
Primary Completion Date:
2017-06-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-07-14
Completion Date Type:
ACTUAL
First Submit Date:
2016-04-27
First Submit QC Date:
None
Study First Post Date:
2016-04-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-06-15
Results First Submit QC Date:
None
Results First Post Date:
2018-07-31
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-07-30
Last Update Post Date:
2018-08-28
Last Update Post Date Type:
ACTUAL